These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 22443187

  • 21. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.
    Salameh TS, Rhea EM, Talbot K, Banks WA.
    Biochem Pharmacol; 2020 Oct; 180():114187. PubMed ID: 32755557
    [Abstract] [Full Text] [Related]

  • 22. Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases.
    Chen SD, Chuang YC, Lin TK, Yang JL.
    Eur J Pharmacol; 2023 Jan 05; 938():175439. PubMed ID: 36470445
    [Abstract] [Full Text] [Related]

  • 23. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Liu W, Jalewa J, Sharma M, Li G, Li L, Hölscher C.
    Neuroscience; 2015 Sep 10; 303():42-50. PubMed ID: 26141845
    [Abstract] [Full Text] [Related]

  • 24. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
    Zhang L, Zhang L, Li Y, Li L, Melchiorsen JU, Rosenkilde M, Hölscher C.
    J Parkinsons Dis; 2020 Sep 10; 10(2):523-542. PubMed ID: 31958096
    [Abstract] [Full Text] [Related]

  • 25. Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.
    Quast DR, Schenker N, Menge BA, Nauck MA, Kapitza C, Meier JJ.
    Diabetes Care; 2020 Sep 10; 43(9):2137-2145. PubMed ID: 32647054
    [Abstract] [Full Text] [Related]

  • 26. Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.
    McKay NJ, Kanoski SE, Hayes MR, Daniels D.
    Am J Physiol Regul Integr Comp Physiol; 2011 Dec 10; 301(6):R1755-64. PubMed ID: 21975647
    [Abstract] [Full Text] [Related]

  • 27. Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.
    Irwin N, Flatt PR, Patterson S, Green BD.
    Eur J Pharmacol; 2010 Feb 25; 628(1-3):268-73. PubMed ID: 19917278
    [Abstract] [Full Text] [Related]

  • 28. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.
    Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR.
    Endocrinology; 2011 Aug 25; 152(8):3103-12. PubMed ID: 21693680
    [Abstract] [Full Text] [Related]

  • 29. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.
    Lund A, Knop FK, Vilsbøll T.
    Eur J Intern Med; 2014 Jun 25; 25(5):407-14. PubMed ID: 24694879
    [Abstract] [Full Text] [Related]

  • 30. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J, Gallwitz B.
    Diabetes Obes Metab; 2014 Aug 25; 16(8):673-88. PubMed ID: 24373150
    [Abstract] [Full Text] [Related]

  • 31. Lixisenatide for the treatment of type 2 diabetes.
    Petersen AB, Knop FK, Christensen M.
    Drugs Today (Barc); 2013 Sep 25; 49(9):537-53. PubMed ID: 24086950
    [Abstract] [Full Text] [Related]

  • 32. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
    Gallwitz B.
    Drugs; 2011 Sep 10; 71(13):1675-88. PubMed ID: 21902291
    [Abstract] [Full Text] [Related]

  • 33. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL.
    BMJ; 2012 Jan 10; 344():d7771. PubMed ID: 22236411
    [Abstract] [Full Text] [Related]

  • 34. Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro.
    Li XN, Bu HM, Ma XH, Lu S, Zhao S, Cui YL, Sun J.
    Exp Clin Endocrinol Diabetes; 2017 Feb 10; 125(2):91-97. PubMed ID: 28008585
    [Abstract] [Full Text] [Related]

  • 35. Lixisenatide requires a functional gut-vagus nerve-brain axis to trigger insulin secretion in controls and type 2 diabetic mice.
    Charpentier J, Waget A, Klopp P, Magnan C, Cruciani-Guglielmacci C, Lee SJ, Burcelin R, Grasset E.
    Am J Physiol Gastrointest Liver Physiol; 2018 Nov 01; 315(5):G671-G684. PubMed ID: 30070580
    [Abstract] [Full Text] [Related]

  • 36. The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype.
    Vinué Á, Navarro J, Herrero-Cervera A, García-Cubas M, Andrés-Blasco I, Martínez-Hervás S, Real JT, Ascaso JF, González-Navarro H.
    Diabetologia; 2017 Sep 01; 60(9):1801-1812. PubMed ID: 28608285
    [Abstract] [Full Text] [Related]

  • 37. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin-Efe A, Filippaios A, Bowers J, Srnka A, Gavrieli A, Ko BJ, Liakou C, Kanyuch N, Tseleni-Balafouta S, Mantzoros CS.
    Diabetologia; 2016 May 01; 59(5):954-65. PubMed ID: 26831302
    [Abstract] [Full Text] [Related]

  • 38. Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment.
    Gejl M, Brock B, Egefjord L, Vang K, Rungby J, Gjedde A.
    Sci Rep; 2017 Dec 13; 7(1):17490. PubMed ID: 29235507
    [Abstract] [Full Text] [Related]

  • 39. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice.
    Baggio LL, Ussher JR, McLean BA, Cao X, Kabir MG, Mulvihill EE, Mighiu AS, Zhang H, Ludwig A, Seeley RJ, Heximer SP, Drucker DJ.
    Mol Metab; 2017 Nov 13; 6(11):1339-1349. PubMed ID: 29107282
    [Abstract] [Full Text] [Related]

  • 40. Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes.
    Aung MM, Slade K, Freeman LAR, Kos K, Whatmore JL, Shore AC, Gooding KM.
    Diabetologia; 2019 Sep 13; 62(9):1701-1711. PubMed ID: 31203378
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.